Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 2/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12929868 | 1.00 | THRB (0.64) | THRBALDH1A1TSHRACLYVCAM1 | |
| SCHEMBL30400000 | 1.00 | THRB (0.64) | THRBALDH1A1TSHRACLYVCAM1 | |
| SCHEMBL16769632 | 1.00 | THRB (0.64) | THRBALDH1A1TSHRACLYVCAM1 | |
| SCHEMBL14589534 | 1.00 | THRB (0.64) | THRBALDH1A1TSHRACLYVCAM1 | |
| SCHEMBL14308119 | 0.97 | THRB (0.59) | THRBALDH1A1TSHRACLYVCAM1 | |
| SCHEMBL8057710 | 0.89 | THRB (0.55) | THRBALDH1A1TSHRACLYVCAM1 | |
| SCHEMBL517575 | 0.86 | THRB (0.82) | THRBALDH1A1TSHRACLY | |
| SCHEMBL713583 | 0.86 | THRB (0.82) | THRBALDH1A1TSHRACLY | |
| SCHEMBL714887 | 0.86 | THRB (0.82) | THRBALDH1A1TSHRACLY | |
| SCHEMBL8563271 | 0.86 | THRB (0.82) | THRBALDH1A1TSHRACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240291009-A1 | METHOD FOR PURIFYING TREATMENT TARGET SOLUTION | AGC Inc. (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4417582-A1 | METHOD FOR PURIFYING TREATMENT TARGET SOLUTION | AGC Inc. (JP) | 2024-08-21 | — | — | EP | disclosed |
| CN-118176168-A | Method for purifying liquid to be treated | ＡＧＣ株式会社 | 2024-06-11 | — | — | CN | disclosed |
| WO-2023063339-A1 | METHOD FOR PURIFYING TREATMENT TARGET SOLUTION | ＡＧＣ株式会社 | 2023-04-20 | — | — | WO | disclosed |
| US-9127088-B2 | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20130123178-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123178-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | GIPR, GLP1R, GCGR | THRB 105/4885ALDH1A1 3308/4885TSHR 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.